Journal ArticleOPEN ACCESS

Lisdexamfetamine: new second‐line treatment option in ADHD

  • Chaplin S
  • Hayward D
Prescriber (2013) 24(19) 31-34
DOI: 10.1002/psb.1112
N/ACitations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Lisdexamfetamine is a prodrug of dexamfetamine indicated for the treatment of ADHD. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Dr David Hayward discusses its place in treatment compared with methylphenidate.

Cite

CITATION STYLE

APA

Chaplin, S., & Hayward, D. (2013). Lisdexamfetamine: new second‐line treatment option in ADHD. Prescriber, 24(19), 31–34. https://doi.org/10.1002/psb.1112

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free